407 related articles for article (PubMed ID: 15658855)
1. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
[TBL] [Abstract][Full Text] [Related]
2. Fragment-based lead discovery using X-ray crystallography.
Hartshorn MJ; Murray CW; Cleasby A; Frederickson M; Tickle IJ; Jhoti H
J Med Chem; 2005 Jan; 48(2):403-13. PubMed ID: 15658854
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
[TBL] [Abstract][Full Text] [Related]
4. Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.
Liu Q; Masek B; Smith K; Smith J
J Med Chem; 2007 Nov; 50(22):5392-402. PubMed ID: 17918924
[TBL] [Abstract][Full Text] [Related]
5. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
Frembgen-Kesner T; Elcock AH
J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
[TBL] [Abstract][Full Text] [Related]
6. Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.
Hammach A; Barbosa A; Gaenzler FC; Fadra T; Goldberg D; Hao MH; Kroe RR; Liu P; Qian KC; Ralph M; Sarko C; Soleymanzadeh F; Moss N
Bioorg Med Chem Lett; 2006 Dec; 16(24):6316-20. PubMed ID: 17010605
[TBL] [Abstract][Full Text] [Related]
7. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase.
Congreve M; Aharony D; Albert J; Callaghan O; Campbell J; Carr RA; Chessari G; Cowan S; Edwards PD; Frederickson M; McMenamin R; Murray CW; Patel S; Wallis N
J Med Chem; 2007 Mar; 50(6):1124-32. PubMed ID: 17315857
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
9. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
Trejo A; Arzeno H; Browner M; Chanda S; Cheng S; Comer DD; Dalrymple SA; Dunten P; Lafargue J; Lovejoy B; Freire-Moar J; Lim J; Mcintosh J; Miller J; Papp E; Reuter D; Roberts R; Sanpablo F; Saunders J; Song K; Villasenor A; Warren SD; Welch M; Weller P; Whiteley PE; Zeng L; Goldstein DM
J Med Chem; 2003 Oct; 46(22):4702-13. PubMed ID: 14561090
[TBL] [Abstract][Full Text] [Related]
11. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
12. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
[TBL] [Abstract][Full Text] [Related]
13. Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase.
McClure KF; Abramov YA; Laird ER; Barberia JT; Cai W; Carty TJ; Cortina SR; Danley DE; Dipesa AJ; Donahue KM; Dombroski MA; Elliott NC; Gabel CA; Han S; Hynes TR; Lemotte PK; Mansour MN; Marr ES; Letavic MA; Pandit J; Ripin DB; Sweeney FJ; Tan D; Tao Y
J Med Chem; 2005 Sep; 48(18):5728-37. PubMed ID: 16134941
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).
Moffett K; Konteatis Z; Nguyen D; Shetty R; Ludington J; Fujimoto T; Lee KJ; Chai X; Namboodiri H; Karpusas M; Dorsey B; Guarnieri F; Bukhtiyarova M; Springman E; Michelotti E
Bioorg Med Chem Lett; 2011 Dec; 21(23):7155-65. PubMed ID: 22014550
[TBL] [Abstract][Full Text] [Related]
15. Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode.
Angell RM; Bamborough P; Cleasby A; Cockerill SG; Jones KL; Mooney CJ; Somers DO; Walker AL
Bioorg Med Chem Lett; 2008 Jan; 18(1):318-23. PubMed ID: 18006306
[TBL] [Abstract][Full Text] [Related]
16. Displacement assay for the detection of stabilizers of inactive kinase conformations.
Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
18. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.
Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M
Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461
[TBL] [Abstract][Full Text] [Related]
19. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.
Szczepankiewicz BG; Kosogof C; Nelson LT; Liu G; Liu B; Zhao H; Serby MD; Xin Z; Liu M; Gum RJ; Haasch DL; Wang S; Clampit JE; Johnson EF; Lubben TH; Stashko MA; Olejniczak ET; Sun C; Dorwin SA; Haskins K; Abad-Zapatero C; Fry EH; Hutchins CW; Sham HL; Rondinone CM; Trevillyan JM
J Med Chem; 2006 Jun; 49(12):3563-80. PubMed ID: 16759099
[TBL] [Abstract][Full Text] [Related]
20. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]